Pharmacie Principale Revenue and Competitors
Estimated Revenue & Valuation
- Pharmacie Principale's estimated annual revenue is currently $25.4M per year.
- Pharmacie Principale's estimated revenue per employee is $270,000
Employee Data
- Pharmacie Principale has 94 Employees.
- Pharmacie Principale grew their employee count by -2% last year.
Pharmacie Principale's People
Name | Title | Email/Phone |
---|
Pharmacie Principale Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $71M | 239 | 20% | N/A | N/A |
#2 | $8M | 37 | 9% | N/A | N/A |
#3 | $177.2M | 525 | -19% | N/A | N/A |
#4 | $126.6M | 375 | -2% | N/A | N/A |
#5 | $16M | 66 | 20% | N/A | N/A |
#6 | $45.7M | 154 | 15% | N/A | N/A |
#7 | $116.2M | 339 | 13% | $117M | N/A |
#8 | $108.4M | 316 | 2% | $440.7K | N/A |
#9 | $122.5M | 363 | 14% | N/A | N/A |
#10 | $50.2M | 169 | 34% | N/A | N/A |
What Is Pharmacie Principale?
Pharmacie Principale S.A. is a professions médicales company based out of Geneva, Geneva, Switzerland.
keywords:N/AN/A
Total Funding
94
Number of Employees
$25.4M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pharmacie Principale News
2022-04-19 - Des comprimés contre la COVID-19 disponibles en pharmacie ...
: Les deux principales contre-indications sont les problèmes de foie et de reins sévères. Le principal enjeu, c'est que le Paxlovid interagit...
2022-04-13 - Médecins et pharmacies de garde du dimanche 10 avril
Nanteuil-en-Vallée: Pharmacie Fouché, 1, rue du Moulin de la Tâche, 05.45.31.82.68. Roullet-Saint-Estèphe: Pharmacie Principale, 22,...
2022-03-30 - De garde ce dimanche 27 mars
Pharmacie principale Prat-Gaubert, 26 rue Vincent-Mir, à Saint-Lary-Soulan (jusqu'à lundi 9 heures). Tél. 05 62 39 40 25 ; fax : 05 62 40 03...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $25.7M | 95 | 17% | N/A |
#2 | $13.9M | 96 | 19% | N/A |
#3 | $13.9M | 96 | -5% | N/A |
#4 | N/A | 97 | 33% | N/A |
#5 | $14.2M | 98 | 40% | N/A |